RecruitingPhase 2NCT05808764
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
A Phase II, Open-label Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
Sponsor
Hoffmann-La Roche
Enrollment
10 participants
Start Date
Apr 26, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.
Eligibility
Max Age: 19 Days
Inclusion Criteria6
- Male or female newborn infant aged <20 days at first dose
- Newborn infants with genetic diagnosis of 5q-autosomal recessive SMA or newborn infants identified as positive for SMA via newborn screening or via prenatal testing.
- Gestational age equal to or greater than 37 weeks
- Receiving adequate nutrition and hydration at the time of screening
- Adequately recovered from any acute illness at baseline and considered well enough to participate in the study
- Parent/caregiver is willing to consider nasogastric, nasojejunal, or gastrostomy tube placement during the study to maintain safe hydration, nutrition, and treatment delivery, if recommended by the investigator.
Exclusion Criteria7
- Presence of clinical symptoms or signs consistent with SMA Type 0
- In the opinion of the investigator, inadequate venous or capillary blood access for the study procedures
- Systolic blood pressure or diastolic blood pressure or heart rate abnormalities
- Presence of clinically relevant electrocardiogram (ECG) abnormalities
- The infant (or the person breastfeeding the infant) taking any of the following: any inhibitor of CYP3A4 taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing, any inducer of CYP3A4 taken within 4 weeks (or within 5 times the elimination half-life, whichever is longer prior to dosing, and/or use of any multidrug and toxin extrusion (MATE) substrates taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing
- Concurrent or previous administration of nusinersen or onasemnogene abeparvovec
- Clinically significant abnormalities in laboratory test
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRisdiplam
Participants will receive 0.15 mg/kg risdiplam orally once daily for 28 days.
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05808764
Related Trials
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
NCT0586199919 locations
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
NCT0586198616 locations
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
NCT0655541919 locations
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
NCT0578975814 locations
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
NCT072216692 locations